AZoLifeSciences on MSN
Using AI and "Protein Language" Models to Speed Monoclonal Antibody Design
Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or ...
M2T-CD33 (LTI-214) has received FDA orphan drug designation, offering incentives like tax credits and market exclusivity for AML treatment. The treatment targets CD33, a glycoprotein present in 90% of ...
The TL1a inhibitor duvakitug was effective at 14 weeks in patients who had previous exposure to conventional and advanced ...
Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or ...
Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or ...
Primary nephrotic syndrome in adults, including minimal-change nephrotic syndrome, has an incidence of roughly 0.2 to 0.8 per ...
Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback